PPF Group

PPF Group operates in 25 countries, investing in multiple sectors, including financial services, telecommunications, media, biotechnology, real estate, and engineering. PPF Group’s reach spans from Europe to North America and across Asia. The Group owns assets to the value of EUR 43.5 billion and employs 50,000 people globally (as at 30 June 2023). For more information visit PPF Group.

SOTIO Biotech is leading the biotechnology efforts of PPF Group by building a diverse portfolio through its in-house research and development, collaborations with external partners, in-licensing deals, investments and acquisitions. 

As part of the PPF Group, SOTIO closely cooperates with its partners to drive preclinical and clinical development for projects added to the SOTIO pipeline. The aim is to rapidly advance these projects to clinical trials and towards commercialization. To date, SOTIO has established partnerships regarding the interleukin-15 (IL-15) superagonist program and NBE-Therapeutics (Switzerland) regarding a new Antibody-Drug Conjugate program. In addition to SOTIO, PPF also invested in Cytune Pharma, NBE-Therapeutics, Cellestia Biotech (Switzerland) and Autolus Therapeutics (UK).

Subscribe to news